GovChime
Notice ID: a2b5470efb094112bde07eeb592d9a8bCombined Synopsis/Solicitation

cGMP Mitragynine HCl Supplemental Stability & Analytical Activities

Archived on August 30, 2024. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
12:00 PM UTC−04:00
Posted
August 7, 2024
Notice type
Combined Synopsis/Solicitation
NAICS
541380: Testing Laboratories and Services
Agency
Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH

Notice details

Office
NATIONAL INSTITUTES OF HEALTH NIDA
Place of performance
Albany, NY, 12203
Last updated
Dec 4, 2025

Identifiers

Solicitation number
75N95024Q00480
Notice ID
a2b5470efb094112bde07eeb592d9a8b

Description

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in Subpart 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation; proposals are being requested and a written solicitation will not be issued. The solicitation number is 75N95024Q00480 and the solicitation is issued as a request for quotation (RFQ). This acquisition is for a commercial item or service and is conducted under the authority of the Federal Acquisition Regulation (FAR) Part 13 Simplified Acquisition Procedures; and FAR Part 12 Acquisition of Commercial Items, and is not expected to exceed the simplified acquisition threshold. THIS IS A NON-COMPETITIVE (NOTICE OF INTENT) COMBINED SYNOPSIS SOLICITATION TO AWARD A CONTRACT OR PURCHASE ORDER WITHOUT PROVIDING FOR FULL OR OPEN COMPETITION (INCLUDING BRAND-NAME). The National Institute on Drug Abuse (NIDA), Office of Acquisition (OA), on behalf of the National Center for Advancing Translational Sciences (NCATS), intends to negotiate and award a purchase order without providing for full and open competition (including brand-name) to Curia Global, Inc., 26 Corporate Circle Albany, New York 12203 for cGMP Mitragynine HCl Supplemental Stability & Analytical Activities. This acquisition is conducted as non-competitive for a commercial item or service and is conducted pursuant to FAR 13.106-1(b)(1). The Therapeutic Development Branch (TDB) at the National Center for Advancing Translational Sciences (NCATS) is conducting a preclinical development of Mitragynine (MG) to support its clinical evaluation, as part of the Helping to End Addiction Long-term initiative (HEAL). The Contractor shall provide long term stability studies on two cGMP batches of Mitragynine HCl and requalify cGMP reference standard of Mitragynine HCl annually for up to 3 years. See Attachment 1 - Statement of Work.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:75N95024Q00480
  1. Combined Synopsis
  1. Combined SynopsisCurrentAug 7, 2024

    cGMP Mitragynine HCl Supplemental Stability & Analytical Activities

    Notice a2b5470efb094112bde07eeb592d9a8b on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline

Additional Details

Solicitation Number

75N95024Q00480

Archive Date

Aug 30, 2024

Office Address

Bethesda, MD, 20892